Theme

Creo Medical Group

CREOHealthcare
12.09GBX
-0.29%
Market Cap
49.87M
Volume
18.65k
4% of avg
P/E Ratio
-4.10
EPS (TTM)
-2.95
Beta
0.56
Day Range
12.00p - 12.25p
52 Week Range
9.22p12.09p32.50p
12.09p

Upcoming Events

22 September 2025
Announcement of Creo Medical's unaudited interim results
24 September 2025
Live online presentation of Creo Medical's interim results
30 September 2025
Announcement of unaudited interim results for the six months ended 30 June 2025
High Impact Event
9 October 2025
Capital Markets Event for investors and analysts
High Impact Event
May 2026
Expected release of FY2025 financial results
High Impact Event
CREO
NEUTRAL

Creo Medical Group Announces Holding Change

The healthcare company has announced a change in its major shareholding, with M&G Plc increasing its stake to over 12%.

CREO
NEUTRAL

Creo Medical Announces Interim Results Presentation

The medical device company will announce its interim results and host an online investor presentation.

CREO
NEUTRAL

Creo Medical Group CFO Transfers Shares to Children

The medical device company's CFO has transferred a portion of his shareholding to his children.

CREO
NEUTRAL

Creo Medical highlights successful Speedboat® procedure for patient

The medical device company shares a patient testimonial highlighting the benefits of its Speedboat® technology, which helped a patient avoid major surgery.

CREO
NEUTRAL

Creo Medical Group Awards Shares Under SIP, Directors Increase Stake

The medical device company has awarded shares to employees and directors under its Share Incentive Plan.

CREO
GOOD

Creo Medical Reports 40% Core Technology Revenue Growth in H1'25

The medical device company reports 40% growth in core technology revenues in the first half of 2025, in line with expectations, and is tracking on plan for full-year guidance.

CREO
NEUTRAL

Creo Medical Begins Landmark Lung Tumour Clinical Study for MicroBlate™ Flex

The medical device company has commenced a new clinical study evaluating the safety and performance of its MicroBlate™ Flex device for treating lung tumours.

CREO
NEUTRAL

Creo Medical Group Announces PDMR Options Revision

The medical device company has revised the exercise price of options granted to certain PDMRs.

CREO
NEUTRAL

Creo Medical Appoints Deutsche Bank as New Nominated Adviser

The medical device company has appointed Deutsche Bank AG, London Branch as its new Nominated Adviser and Broker, replacing Numis Securities Limited.

CREO
NEUTRAL

Creo Medical Provides AGM Update, Announces Board Changes

The medical device company provides an update ahead of its AGM, announcing board changes and highlighting progress in its core technology and product pipeline.